剂量/方案调整的Rd-R与持续Rd方案在老年中等体能初诊多发性骨髓瘤患者中的随机对照研究
该随机3期研究纳入199例老年中等体能初诊多发性骨髓瘤患者,比较剂量/方案调整的Rd-R方案(9周期Rd后改为每日10mg来那度胺维持、不加地塞米松)与持续Rd方案的疗效与可行性。
要点
- Rd-R方案可行,因不良事件停用来那度胺比例24% vs 30%,减量比例45% vs 62%。
核心结论
- 在老年中等体能初诊多发性骨髓瘤患者中,9个周期Rd后转换为减量来那度胺维持(每日10mg、不加地塞米松)的方案可行,结局与标准持续Rd相似。
研究设计与样本
- 随机3期研究,共199例可评估的老年中等体能初诊多发性骨髓瘤患者,101例接受Rd-R方案,98例接受持续Rd方案,中位随访37个月。
主要发现
- 因不良事件停用来那度胺比例Rd-R组 vs 持续Rd组为24% vs 30%,来那度胺减量比例分别为45% vs 62%。
临床怎么用
- 对于老年中等体能初诊多发性骨髓瘤患者,可考虑在9个周期Rd后转换为减量来那度胺维持(每日10mg、不加地塞米松)以提高无事件生存并减少治疗负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide-dexamethasone (Rd) is standard treatment for elderly patients with multiple myeloma (MM). In this randomized phase 3 study, we investigated efficacy and feasibility of dose/schedule-adjusted Rd followed by maintenance at 10 mg per day without dexamethasone (Rd-R) vs continuous Rd in elderly, intermediate-fit newly diagnosed patients with MM. Primary end point was event-free survival (EFS), defined as progression/death from any cause, lenalidomide discontinuation, or hematologic grade 4 or nonhematologic grade 3 to 4 adverse event (AE). Of 199 evaluable patients, 101 received Rd-R and 98 continuous Rd. Median follow-up was 37 months. EFS was 10.4 vs 6.9 months (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.51-0.95; P = .02); median progression-free survival, 20.2 vs 18.3 months (HR, 0.78; 95% CI, 0.55-1.10; P = .16); and 3-year overall survival, 74% vs 63% (HR, 0.62; 95% CI, 0.37-1.03; P = .06) with Rd-R vs Rd, respectively. Rate of ≥1 nonhematologic grade ≥3 AE was 33% vs 43% (P = .14) in Rd-R vs Rd groups, with neutropenia (21% vs 18%), infections (10% vs 12%), and skin disorders (7% vs 3%) the most frequent; constitutional and central nervous system AEs mainly related to dexamethasone were more frequent with Rd. Lenalidomide was discontinued for AEs in 24% vs 30% and reduced in 45% vs 62% of patients receiving Rd-R vs Rd, respectively. In intermediate-fit patients, switching to reduced-dose lenalidomide maintenance without dexamethasone after 9 Rd cycles was feasible, with similar outcomes to standard continuous Rd. This trial was registered at www.clinicaltrials.gov as #NCT02215980.
引用
- Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021. PMID: 33739404. doi:10.1182/blood.2020009507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。